Compare Alcon AG (ALC) vs Davita Inc (DVA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Davita Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Davita Inc trades at $230.13 (market cap $15.04B). The key difference: Alcon AG is far larger — about 2.2× Davita Inc's market cap, and Alcon AG pays a 0.54% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| ALC | DVA | |
|---|---|---|
Market Cap | $32.69B | $15.04B |
Sector | Health | Health |
52-Week High | $92.22 | $235.71 |
52-Week Low | $62.02 | $103.87 |
Enterprise Value | $36.28B | $27.59B |
Dividend Yield | 0.54% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
